Mehdi Khellaf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10793481/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database. PLoS ONE, 2021, 16, e0253986.	2.5	21
2	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ, The, 2020, 369, m1844.	6.0	355
3	Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study. Internal Medicine Journal, 2019, 49, 1154-1162.	0.8	15
4	Autologous ¹¹¹ Indiumâ€oxinateâ€labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptorâ€agonists. British Journal of Haematology, 2019, 186, e44-e47.	2.5	8
5	A randomized and doubleâ€blind controlled trial evaluating the safety and efficacy of rituximab for warm autoâ€immune hemolytic anemia in adults (the RAIHA study). American Journal of Hematology, 2017, 92, 23-27.	4.1	84
6	Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine (United States), 2016, 95, e5098.	1.0	67
7	Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. American Journal of Hematology, 2016, 91, E499-E501.	4.1	20
8	Autologous 111 Indium-Oxinate-Labelled Platelet Sequestration Study in Patients with Immune Thrombocytopenia Treated By Thrombopoietic Receptor-Agonists. Blood, 2016, 128, 2555-2555.	1.4	0
9	A Multi-Centre Randomized and Double-Blind Controlled Trial of Rituximab for Warm Autoimune Hemolytic Anemia in Adults. Blood, 2015, 126, 3338-3338.	1.4	1
10	Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single enter experience with 60 patients. American Journal of Hematology, 2014, 89, E150-5.	4.1	111
11	The temporary use of thrombopoietinâ€receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. British Journal of Haematology, 2014, 165, 865-869.	2.5	110
12	Hydroxychloroquine is a good secondâ€line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. American Journal of Hematology, 2014, 89, 194-198.	4.1	40
13	Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood, 2013, 121, 2596-2606.	1.4	179
14	A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica, 2013, 98, 881-887.	3.5	78
15	Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood, 2011, 118, 4338-4345.	1.4	104
16	Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis. Annals of Hematology, 2011, 90, 441-446.	1.8	16
17	Characteristics and outcome of immune thrombocytopenia in elderly: Results from a single center caseâ€controlled study. American Journal of Hematology, 2011, 86, 980-984.	4.1	48
18	Impact of Pregnancy On the Course of Immune Thrombocytopenic Purpura: An Observational Study On 44 Cases Blood. 2009. 114. 1320-1320.	1.4	2

Mehdi Khellaf

#	Article	IF	CITATIONS
19	Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. British Journal of Haematology, 2008, 142, 638-643.	2.5	67
20	Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood, 2008, 112, 999-1004.	1.4	227
21	Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica, 2005, 90, 829-32.	3.5	128